GeneTx Biotherapeutics

GeneTx Biotherapeutics LLC was a private biotechnology company that pioneered antisense oligonucleotide (ASO) therapy development for [Angelman syndrome](/diseases/angelman-syndrome), a rare neurogenetic disorder caused by loss of maternal expression of the [UBE3A](/genes/ube3a) gene. GeneTx was acquired by [Ultragenyx Pharmaceutical](/companies/ultragenyx) in 2019 for over $400M, and its lead program GTX-102 is now in late-stage development with a BLA submission expected in Q3-Q4 2026[uxeacq].

History

GeneTx Biotherapeutics LLC was a private biotechnology company that pioneered antisense oligonucleotide (ASO) therapy development for [Angelman syndrome](/diseases/angelman-syndrome), a rare neurogenetic disorder caused by loss of maternal expression of the [UBE3A](/genes/ube3a) gene. GeneTx was acquired by [Ultragenyx Pharmaceutical](/companies/ultragenyx) in 2019 for over $400M, and its lead program GTX-102 is now in late-stage development with a BLA submission expected in Q3-Q4 2026[uxeacq].

History

Founding and Early Development (2017-2019)

GeneTx was founded in 2017 by Dr. Allyson Berent and Dr. Steven Bleyman, parents of a child with Angelman syndrome, along with Dr. Eric Goedken. The company was established with a focus on developing an ASO therapy that could reactivate the silenced paternal [UBE3A](/genes/ube3a) allele — effectively restoring gene expression without requiring exogenous gene delivery[genetx2022].

Key founding insight: Angelman syndrome results from loss of maternal UBE3A in neurons, but the paternal allele is present and silent. An ASO targeting the [UBE3A](/genes/ube3a)-antisense transcript (UBE3A-ATS) could unsilence the paternal allele, restoring functional UBE3A protein expression.

Acquisition by Ultragenyx (2019):

• Ultragenyx acquired GeneTx for $400M+, recognizing the potential of GTX-102
• GeneTx became a subsidiary operating under Ultragenyx's rare disease focus
• Continued development of GTX-102 from Phase 1 through Phase 2[uxeacq]

Clinical Development (2019-2026)

Under Ultragenyx, GTX-102 progressed through clinical development:

• Phase 1/2 (KIK-AS-02): Dose escalation to assess safety and efficacy
• Phase 2: Registration-directed study ongoing
• BLA submission: Q3-Q4 2026 anticipated[uxe2026]

GTX-102 Program

Mechanism of Action

GTX-102 is an antisense oligonucleotide that targets the [UBE3A](/genes/ube3a)-antisense transcript (UBE3A-ATS), which is responsible for silencing the paternal [UBE3A](/genes/ube3a) allele in neurons. By inhibiting UBE3A-ATS, GTX-102 can reactivate expression of the paternal allele, restoring functional UBE3A protein in affected neurons[genetx2024].

Key features:

• Disease-modifying: Addresses the root cause of Angelman syndrome
• Allele-selective: Only reactivates the silenced paternal allele (already present but epigenetically silenced)
• CNS-targeted: Intrathecal administration to ensure adequate CNS exposure
• Repeatable dosing: ASO approach allows for repeat administration

Angelman Syndrome Background

[Angelman syndrome](/diseases/angelman-syndrome) is a rare neurogenetic disorder characterized by:

• Severe intellectual disability
• Developmental delay
• Movement and balance disorders (ataxia)
• Seizures (often refractory)
• Lack of speech development
• Characteristic behavioral features (happy demeanor, easily startled)

Clinical Trial Data

KIK-AS-02 (Phase 1/2, NCT04259281):

• Dose escalation study in patients with Angelman syndrome
• Primary endpoints: Safety and tolerability
• Secondary endpoints: Clinical efficacy measures (Bayley-3, CGI-C, seizure frequency)
• Results showed dose-dependent UBE3A reactivation and encouraging clinical improvements at higher dose levels[genetx2024]

• Registration-directed cohort expansion
• Multiple dose levels to confirm optimal regimen
• Key efficacy endpoints: developmental/functional assessments
• Results anticipated to support BLA filing[uxe2024]

Regulatory Status (March 2026)

• Phase 2 completed
• BLA preparation underway
• Submission expected Q3-Q4 2026
• Orphan Drug Designation: Active
• Rare Pediatric Disease PRV: Expected to be awarded upon approval

Platform Technology: UBE3A-ATS ASO

GeneTx's ASO approach targets the non-coding [UBE3A](/genes/ube3a)-antisense transcript (UBE3A-ATS) that naturally silences the paternal allele during neuronal development. This approach:

Financial and Corporate Structure

| Item | Detail |
|------|--------|
| Founded | 2017 |
| Acquired by | [Ultragenyx Pharmaceutical](/companies/ultragenyx) |
| Acquisition date | 2019 |
| Acquisition value | $400M+ |
| Parent company | Ultragenyx Pharmaceutical (NASDAQ: RARE) |
| Program status | Phase 2, BLA prep |
| Expected BLA submission | Q3-Q4 2026 |

Post-acquisition, GeneTx operates as an integrated Ultragenyx program, with the original founders and team contributing to program development under Ultragenyx leadership[uxeacq].

Competitive Position

GTX-102 competes in the Angelman syndrome therapeutic landscape with:

| Competitor | Approach | Stage |
|-----------|----------|-------|
| Roche | ASO (UBE3A-ATS targeting) | Discovery |
| Ionis Pharmaceuticals | ASO platform | Discovery |
| Encoded Therapeutics | AAV approach (different mechanism) | Preclinical |

GTX-102 advantages:

• Most advanced program in Angelman gene therapy (Phase 2, BLA imminent)
• ASO approach has clear regulatory precedent
• Reactivation of existing allele (no gene addition)
• Repeatable dosing allows for dose optimization

• Long-term follow-up required for ASO durability
• Intrathecal delivery burden
• Optimal dosing still being established

Key Publications and Presentations

Hub Page Cross-Links

• [AAV Gene Therapy for Neurodevelopmental Epilepsy — Hub](/therapeutics/aav-gene-therapy-neurodevelopmental-epilepsy)](/therapeutics)
• [Angelman Syndrome Disease Page](/diseases/angelman-syndrome)](/diseases/angelman-syndrome)
• [UBE3A Gene Page](/genes/ube3a)](/genes)
• [GTX-102 Clinical Trial Page](/clinical-trials/gtx102-angelman-syndrome-phase-1-2)
• [Ultragenyx Pharmaceutical](/companies/ultragenyx)